Research Overview
· Last Reviewed May 3, 2026· PSI Editorial Board· IndependentCan Peptides Help With Peripheral Artery Disease (PAD)?
The honest map across 8 PAD scenarios — what is FDA-approved, where validated antiplatelets and cilostazol rule, and what STRIDE actually showed.
WHICH PAD CONTEXT?
PAD Context
Animal Studies
Human Trials
Symptomatic claudication management
FDA-approved cilostazol primary
PAD secondary prevention antiplatelet
validated antiplatelet therapy
PAD with type 2 diabetes
FDA-approved GLP-1 RA CV indications
PAD requiring foundational LDL reduction
validated statin first-line
Critical limb-threatening ischemia (CLTI)
vascular surgery revascularization
PAD with active smoking
smoking cessation foundational
PAD with obesity contributor
FDA-approved chronic weight management
Phase 3 triple-agonist research access
investigational class context
How counts are scaled → · Tap any row to see the studies →
Quick Answer
PAD has well-characterized validated approaches in clinical practice. Foundations include comprehensive evaluation by primary care, vascular medicine, vascular surgery, or cardiology. Workup covers ankle-brachial index (ABI), lipid panel, ASCVD risk assessment, and smoking history. Additional assessment includes Doppler ultrasound, CT angiography, or MR angiography when indicated.
Validated PAD therapy is foundational. Statins are foundational with substantial outcomes evidence. Aspirin or clopidogrel antiplatelet therapy is appropriate. Cilostazol is FDA-approved specifically for claudication symptoms.
Semaglutide is FDA-approved as Ozempic for T2DM CV benefit. STRIDE Phase 3 demonstrated improvements in PAD walking distance and quality of life.
Liraglutide is FDA-approved as Victoza for T2DM. LEADER trial established cardiovascular outcomes including PAD subgroup data.
Tirzepatide is FDA-approved as Zepbound for chronic weight management. SURPASS-CVOT cardiovascular outcomes trial in T2DM is ongoing.
Retatrutide is investigational with Phase 3 TRIUMPH-1 program at Eli Lilly.
The honest framing: STRIDE provides the first direct GLP-1 RA evidence specifically in PAD. Validated antiplatelets, statins, cilostazol, and smoking cessation remain foundational. For broader context, see Peptides for Cardiovascular Health, Peptides for ASCVD, and Peptides for Type 2 Diabetes.
Semaglutide STRIDE vs validated PAD therapy
First direct GLP-1 RA PAD trial vs established standard of care
Validated PAD care is foundational per AHA/ACC 2016 Lower Extremity PAD Clinical Practice Guideline. Statins (atorvastatin, rosuvastatin) reduce cardiovascular events with substantial Phase 3 outcomes evidence. Antiplatelets including aspirin, clopidogrel, and rivaroxaban (Xarelto) plus aspirin per COMPASS trial reduce ischemic events. Cilostazol (Pletal) is FDA-approved specifically for claudication symptoms. Supervised exercise therapy is Class 1 recommendation with substantial walking distance evidence. Smoking cessation is the most important lifestyle intervention.
Semaglutide STRIDE Phase 3 trial provides the first direct GLP-1 RA peptide evidence specifically in PAD population. The trial enrolled patients with PAD and T2DM and demonstrated improvements in maximum walking distance and quality of life over 52 weeks versus placebo. Mechanism includes weight reduction, improved endothelial function, anti-inflammatory effects, and glycemic control in T2DM. The trial supports semaglutide use in PAD with T2DM as additive therapy alongside validated standard of care.
PSI's reading: validated PAD care including statins, antiplatelets, cilostazol, smoking cessation, and supervised exercise remains foundational per AHA/ACC 2016 Guideline. Semaglutide STRIDE adds direct evidence for walking distance benefits in PAD with T2DM. The compound is appropriate as additive therapy for FDA-approved indications (Ozempic for T2DM CV benefit) under specialty coordination. Semaglutide does not replace validated antiplatelets, statins, or cilostazol.
Antiplatelet options for PAD: aspirin vs clopidogrel vs rivaroxaban
Three FDA-approved antiplatelet strategies
Aspirin (low-dose 81mg) is the most commonly used antiplatelet for PAD with substantial outcomes evidence. CAPRIE trial demonstrated clopidogrel (Plavix) provides modest additional benefit versus aspirin in atherothrombotic disease including PAD. Both agents are FDA-approved with established cardiovascular outcomes evidence per AHA/ACC 2016 PAD Guideline.
COMPASS trial demonstrated rivaroxaban (Xarelto) 2.5mg twice daily plus aspirin 100mg daily reduces major adverse cardiovascular and limb events versus aspirin alone in patients with stable PAD or chronic coronary disease. The combination is FDA-approved for this indication. Bleeding risk requires careful patient selection. Specialty guidance ensures appropriate matching.
PSI's reading: multiple FDA-approved antiplatelet options exist for PAD per AHA/ACC 2016 Guideline. Aspirin alone is appropriate for most patients with stable PAD. Clopidogrel is alternative for aspirin-intolerant patients. Rivaroxaban plus aspirin per COMPASS applies for high-risk patients with stable PAD. Specialty coordination including primary care, vascular medicine, and cardiology ensures appropriate selection considering bleeding risk.
Cilostazol vs supervised exercise therapy for claudication
FDA-approved pharmacotherapy versus Class 1 lifestyle intervention
Cilostazol (Pletal) is the only FDA-approved drug specifically for PAD claudication symptoms. The phosphodiesterase-3 inhibitor improves maximum walking distance through vasodilatory and antiplatelet mechanisms. Phase 3 trials demonstrated approximately 50 percent improvement in maximum walking distance at 24 weeks. Pentoxifylline (Trental) is older alternative with less robust evidence. Contraindications include heart failure.
Supervised exercise therapy is Class 1 recommendation per AHA/ACC 2016 PAD Guideline with substantial outcomes evidence. Structured walking programs typically 30 to 60 minutes three times weekly produce substantial walking distance improvements rivaling or exceeding pharmacotherapy. Home-based exercise programs have growing evidence base. Centers for Medicare and Medicaid Services covers supervised exercise therapy for PAD.
PSI's reading: supervised exercise therapy and cilostazol have complementary roles for symptomatic claudication per AHA/ACC 2016 Guideline. Supervised exercise is foundational with Class 1 recommendation. Cilostazol applies for patients without heart failure when exercise alone insufficient. Combination therapy is appropriate. STRIDE adds semaglutide as additive option for PAD with T2DM. Specialty coordination ensures appropriate matching.
Comprehensive PAD management vs single-modality approach
Integrated multi-factor therapy versus partial intervention
PAD is closely linked to systemic atherosclerosis. Comorbidity often includes coronary artery disease, cerebrovascular disease, hypertension, T2DM, dyslipidemia, and obesity. Comprehensive evaluation per AHA/ACC 2016 identifies all contributing factors. Validated comprehensive management addresses each factor with appropriate therapy under primary care, vascular medicine, vascular surgery, or cardiology specialty guidance.
Comprehensive PAD management addresses each component. Antiplatelets target ischemic events. Statins target LDL with cardiovascular outcomes benefits. Cilostazol targets claudication symptoms. Smoking cessation is the most critical lifestyle intervention. Supervised exercise therapy improves walking distance. ACE inhibitors or ARBs target comorbid hypertension. GLP-1 RA peptides target T2DM and obesity contributors with STRIDE adding direct PAD evidence for semaglutide. Revascularization (endovascular or surgical) applies for CLTI per vascular surgery.
PSI's reading: comprehensive PAD management addresses multiple cardiovascular risk factors with validated FDA-approved therapies under specialty coordination. Single-compound peptide approach addresses only T2DM and metabolic contributors. Validated multi-component framework per AHA/ACC 2016 PAD Guideline + AHA/ACC 2018 Cholesterol + COMPASS antiplatelet evidence provides foundation. Specialty coordination ensures appropriate matching.
The Compounds, Ranked by Evidence
Ordered by strength of controlled human data, not popularity.
Of the 4 peptides discussed for PAD, Semaglutide stands out as the only compound with direct PAD-specific Phase 3 evidence. STRIDE Phase 3 trial demonstrated improvements in walking distance and quality of life in PAD patients with T2DM. Semaglutide also holds FDA approval as Ozempic for T2DM with CV benefit via SUSTAIN-6 and Wegovy for CV risk reduction in obesity without diabetes via SELECT. Liraglutide (Victoza) holds FDA approval for T2DM with cardiovascular benefit via LEADER which included PAD subgroup data. Tirzepatide (Zepbound) holds FDA approval for chronic weight management with SURPASS-CVOT ongoing. Retatrutide is investigational with Phase 3 TRIUMPH-1 program. Validated standard-of-care including statins, antiplatelets (aspirin, clopidogrel, rivaroxaban), cilostazol (Pletal), pentoxifylline, smoking cessation, supervised exercise therapy, and revascularization for CLTI under primary care, vascular medicine, vascular surgery, or cardiology specialty guidance dominates evidence-graded PAD care per AHA/ACC 2016 Lower Extremity PAD Clinical Practice Guideline and 2024 Focused Update.
Semaglutide
FDA-approved Ozempic for T2DM CV benefit + Wegovy for CV risk reduction. STRIDE Phase 3 first direct GLP-1 RA PAD trial demonstrated walking distance and QoL improvements.
Counts are PubMed-indexed papers and registered clinical trials. Scale: Strong 10+, Moderate 4–9, Limited 1–3, None 0. Methodology →
| Context | Animal Studies | Human Trials |
|---|---|---|
PAD walking distance and QoL STRIDE Phase 3 first direct GLP-1 RA PAD trial | 4 Cardiovascular protective effects in animal models including endothelial effects. | 4 STRIDE demonstrated walking distance and QoL improvements in PAD with T2DM. Bonaca 2024 |
Cardiovascular risk reduction FDA-approved CV indication SELECT + SUSTAIN-6 | 6 Cardiovascular protective effects in animal models. | 6 SELECT demonstrated 20 percent reduction in MACE. Lincoff 2023 |
Liraglutide
FDA-approved Victoza for T2DM with cardiovascular benefit. LEADER trial included PAD subgroup data with cardiovascular outcomes benefits.
| Context | Animal Studies | Human Trials |
|---|---|---|
CV outcomes in T2DM with PAD subgroup FDA-approved Victoza CV indication | 6 Cardiovascular protective effects in diabetic animal models. | 6 LEADER demonstrated CV event reduction in T2DM with CV disease including PAD. Marso 2016 |
Tirzepatide
FDA-approved Zepbound for chronic weight management. SURPASS-CVOT cardiovascular outcomes trial in T2DM is ongoing. Not specifically studied in PAD.
| Context | Animal Studies | Human Trials |
|---|---|---|
Cardiometabolic improvements relevant to PAD SURMOUNT + SURPASS-CVOT ongoing | 4 Dual incretin signaling effects on cardiometabolic factors. | 4 SURMOUNT-1 demonstrated approximately 21 percent weight reduction at 72 weeks. Jastreboff 2022 |
Retatrutide
Investigational; Phase 3 TRIUMPH-1 program at Eli Lilly. Triple GLP-1/GIP/glucagon agonist. Not FDA-approved. Not specifically studied in PAD.
| Context | Animal Studies | Human Trials |
|---|---|---|
Cardiometabolic improvements relevant to PAD risk factors Phase 3 TRIUMPH-1 ongoing | 4 Triple incretin signaling effects on cardiometabolic factors. | 2 Phase 2 demonstrated approximately 24 percent weight reduction at 48 weeks. Jastreboff 2023 |
What's Marketed vs What's Studied
7 common claims, corrected.
“GLP-1 receptor agonist peptides replace antiplatelets and statins for PAD.”
GLP-1 receptor agonist peptides do not replace antiplatelets and statins for PAD. Antiplatelets (aspirin, clopidogrel, rivaroxaban per COMPASS) and statins are foundational with substantial outcomes evidence per AHA/ACC 2016. Semaglutide STRIDE provides direct walking distance evidence in PAD with T2DM. The compound is appropriate as additive therapy for FDA-approved cardiovascular indications under specialty coordination. Combination therapy is common in clinical practice.
“Cilostazol is dangerous and rarely used.”
Cilostazol (Pletal) is FDA-approved specifically for PAD claudication symptoms with substantial Phase 3 evidence demonstrating approximately 50 percent improvement in maximum walking distance at 24 weeks. The phosphodiesterase-3 inhibitor is contraindicated in heart failure. Side effects include headache, diarrhea, and palpitations. Specialty guidance ensures appropriate selection. Cilostazol remains an important PAD therapy per AHA/ACC 2016 for patients without heart failure.
“Compounded GLP-1 receptor agonists are equivalent to FDA-approved Ozempic for PAD.”
FDA-approved Ozempic and STRIDE-tested semaglutide have substantial Phase 3 evidence with quality control and regulatory oversight. Compounded peptides outside FDA-approved framework lack equivalent evidence and quality assurance. PAD management relies on validated guideline-directed therapy under primary care, vascular medicine, or cardiology specialty guidance per AHA/ACC 2016.
“Supervised exercise therapy is not as effective as medications.”
Supervised exercise therapy is Class 1 recommendation per AHA/ACC 2016 PAD Guideline with substantial walking distance evidence rivaling or exceeding pharmacotherapy. Centers for Medicare and Medicaid Services covers supervised exercise therapy for PAD. Structured walking programs typically 30 to 60 minutes three times weekly produce substantial improvements. Home-based exercise programs have growing evidence base. Exercise is foundational and complementary to pharmacotherapy.
“All PAD patients need revascularization surgery.”
Revascularization (endovascular angioplasty, stenting, surgical bypass) applies for critical limb-threatening ischemia (CLTI) and for select patients with severe lifestyle-limiting claudication despite optimal medical therapy per AHA/ACC 2016. Most patients with stable claudication are managed with validated medical therapy including antiplatelets, statins, cilostazol, smoking cessation, and supervised exercise. Vascular surgery specialty coordination ensures appropriate matching.
“Smoking cessation is not as important as taking medications for PAD.”
Smoking cessation is the MOST important lifestyle intervention for PAD per AHA/ACC 2016. Smoking is the strongest modifiable risk factor for PAD progression and amputation. Continued smoking substantially reduces effectiveness of all PAD therapies including antiplatelets, statins, and revascularization. Validated smoking cessation tools include varenicline (Chantix), bupropion (Zyban), and nicotine replacement therapy. Counseling and behavioral support enhance success rates.
“I can self-treat PAD with peptides without medical supervision.”
Comprehensive evaluation by primary care, vascular medicine, vascular surgery, or cardiology identifies risk factors and matches treatment per AHA/ACC 2016. Workup includes ankle-brachial index (ABI), lipid panel, ASCVD risk assessment, and smoking history. PAD management requires validated guideline-directed therapy with substantial outcomes evidence. CLTI requires urgent specialty evaluation. Self-treatment bypasses essential clinical assessment and validated framework.
If Considering Use, Here Is How to Be Safe
How to evaluate sources, verify quality, and find qualified physicians.
Get comprehensive PAD evaluation.
Ankle-brachial index (ABI), lipid panel, ASCVD risk assessment, smoking history, and CLTI assessment guide treatment decisions per AHA/ACC 2016.
Establish primary care, vascular medicine, vascular surgery, or cardiology.
Multi-specialty coordination is appropriate for complex disease. Vascular surgery manages CLTI and revascularization. Vascular medicine manages comprehensive medical therapy.
Optimize validated antiplatelet therapy.
Aspirin, clopidogrel, or rivaroxaban (Xarelto) plus aspirin per COMPASS provide validated secondary prevention options per AHA/ACC 2016.
Optimize statin therapy.
Statins are foundational for PAD with substantial cardiovascular outcomes evidence. High-intensity statins for high-risk populations.
Address smoking and exercise.
Smoking cessation is the most important lifestyle intervention. Supervised exercise therapy is Class 1 recommendation per AHA/ACC 2016. CMS covers supervised exercise for PAD.
Approach compounded peptides cautiously.
FDA-approved Ozempic and STRIDE-tested semaglutide have substantial Phase 3 evidence. Compounded peptides outside FDA-approved framework are not validated practice.
The regulatory landscape for PAD peptides is evolving. Semaglutide STRIDE Phase 3 trial published in Lancet 2024 represents the first direct GLP-1 RA peptide trial in PAD population. Tirzepatide SURPASS-CVOT cardiovascular outcomes trial in T2DM is ongoing with anticipated readouts. Retatrutide Phase 3 TRIUMPH-1 program is ongoing. AHA/ACC 2016 Lower Extremity PAD Clinical Practice Guideline + 2024 Focused Update + COMPASS antiplatelet evidence + cilostazol FDA approval provide framework. PSI tracks these developments and updates this page as material changes occur.
Find a verified physician
PSI's directory only lists physicians who have passed a five-gate verification process: state board active, no disciplinary actions, peptide-category competency, transparent pricing, and patient outcome documentation.
Browse the directoryLearn about the verification process →Common Questions
Are any peptides FDA-approved specifically for PAD?
No peptide is FDA-approved specifically for PAD as of 2026. Semaglutide STRIDE Phase 3 trial demonstrated improvements in walking distance and quality of life in PAD with T2DM. Semaglutide holds FDA approval as Ozempic for T2DM CV benefit (SUSTAIN-6) and Wegovy for CV risk reduction (SELECT). Liraglutide holds FDA approval as Victoza for T2DM with LEADER including PAD subgroup. Tirzepatide holds FDA approval as Zepbound for chronic weight management with SURPASS-CVOT ongoing. Retatrutide is investigational. Cilostazol (Pletal) is the only FDA-approved drug specifically for PAD claudication.
What is the STRIDE trial?
STRIDE was a Phase 3 trial of semaglutide 1mg weekly in patients with PAD and T2DM published in Lancet 2024 by Bonaca et al. The trial demonstrated improvements in maximum walking distance and quality of life versus placebo over 52 weeks. STRIDE represents the first direct GLP-1 RA peptide trial specifically in PAD population. The trial supports semaglutide use in PAD with T2DM as additive therapy alongside validated standard of care including antiplatelets, statins, cilostazol, smoking cessation, and supervised exercise.
Should I see a vascular surgeon or vascular medicine specialist for PAD?
Primary care typically manages routine PAD evaluation and risk factor management. Vascular medicine specialty manages comprehensive PAD medical therapy. Vascular surgery specialty manages revascularization for CLTI or severe claudication. Cardiology specialty manages comprehensive cardiovascular risk reduction. Multi-specialty coordination is common for complex PAD. AHA/ACC 2016 framework provides guidance for specialty coordination.
What is the comprehensive evaluation for PAD?
Comprehensive PAD evaluation per AHA/ACC 2016 includes ankle-brachial index (ABI), lipid panel, fasting glucose or HbA1c, basic metabolic panel, smoking history, and ASCVD risk assessment. Additional assessment includes Doppler ultrasound, CT angiography, or MR angiography for select cases. Toe-brachial index applies for non-compressible vessels. Rutherford classification and Fontaine staging guide severity. Cardiovascular evaluation including EKG and echocardiogram applies for select cases.
What is cilostazol and when is it used?
Cilostazol (Pletal) is a phosphodiesterase-3 inhibitor FDA-approved specifically for PAD claudication symptoms. Phase 3 trials demonstrated approximately 50 percent improvement in maximum walking distance at 24 weeks through vasodilatory and antiplatelet mechanisms. The drug is contraindicated in heart failure. Common side effects include headache, diarrhea, and palpitations. Specialty guidance ensures appropriate selection. Pentoxifylline (Trental) is an older alternative with less robust evidence.
What is the COMPASS trial?
COMPASS was a Phase 3 trial of rivaroxaban plus aspirin in patients with stable PAD or chronic coronary disease published in NEJM 2017 by Eikelboom et al. The trial demonstrated rivaroxaban (Xarelto) 2.5mg twice daily plus aspirin 100mg daily reduced major adverse cardiovascular and limb events versus aspirin alone. The combination is FDA-approved for this indication. Bleeding risk requires careful patient selection. Specialty guidance ensures appropriate matching.
What about supervised exercise therapy for PAD?
Supervised exercise therapy is Class 1 recommendation per AHA/ACC 2016 PAD Guideline with substantial walking distance evidence rivaling or exceeding pharmacotherapy. Structured walking programs typically 30 to 60 minutes three times weekly produce substantial improvements in maximum walking distance. Centers for Medicare and Medicaid Services covers supervised exercise therapy for PAD. Home-based exercise programs have growing evidence base. Exercise is foundational and complementary to pharmacotherapy.
What about smoking cessation for PAD?
Smoking cessation is the MOST important lifestyle intervention for PAD per AHA/ACC 2016. Smoking is the strongest modifiable risk factor for PAD progression and amputation. Continued smoking substantially reduces effectiveness of all PAD therapies. Validated smoking cessation tools include varenicline (Chantix), bupropion (Zyban), and nicotine replacement therapy (patches, gum, lozenges). Counseling and behavioral support enhance success rates. Comprehensive PAD management requires smoking cessation as foundational intervention.
What about statins for PAD?
Statins are foundational for PAD per AHA/ACC 2016 with substantial cardiovascular outcomes evidence. High-intensity statins (atorvastatin 40-80mg, rosuvastatin 20-40mg) are appropriate for high-risk populations. Mechanism is HMG-CoA reductase inhibition with hepatic LDL receptor upregulation. PCSK9 inhibitors (Repatha, Praluent), Inclisiran (Leqvio), ezetimibe, and bempedoic acid (Nexletol) provide additional LDL reduction options for residual LDL despite statin.
How do GLP-1 receptor agonists help PAD?
GLP-1 receptor agonists may help PAD through multiple mechanisms documented in cardiovascular outcomes trials. Primary mechanisms include weight reduction, improved endothelial function, anti-inflammatory effects, and glycemic control in T2DM. Semaglutide STRIDE Phase 3 demonstrated direct walking distance and quality of life improvements in PAD with T2DM. The class addresses cardiometabolic contributors to PAD progression. GLP-1 RA peptides do not replace validated antiplatelets, statins, or cilostazol.
What about revascularization for PAD?
Revascularization applies for critical limb-threatening ischemia (CLTI) and for select patients with severe lifestyle-limiting claudication despite optimal medical therapy per AHA/ACC 2016. Endovascular options include angioplasty and stenting. Surgical options include bypass procedures. Vascular surgery specialty coordination is essential for appropriate selection. Most patients with stable claudication are managed with validated medical therapy and supervised exercise.
Are these peptides legal in the United States?
Semaglutide is FDA-approved as Ozempic for T2DM with CV benefit; as Wegovy for chronic weight management and CV risk reduction; as Rybelsus for T2DM by prescription. Liraglutide is FDA-approved as Saxenda for chronic weight management and Victoza for T2DM with CV benefit by prescription. Tirzepatide is FDA-approved as Zepbound by Eli Lilly for chronic weight management by prescription. Retatrutide is investigational. Compounded products outside FDA-approved framework represent non-validated practice.
What is critical limb-threatening ischemia (CLTI)?
Critical limb-threatening ischemia (CLTI), formerly called critical limb ischemia (CLI), is the most severe form of PAD with rest pain, non-healing ulcers, or gangrene. CLTI carries high amputation and mortality risk. Comprehensive evaluation by vascular surgery is urgent. Revascularization (endovascular or surgical) is the primary intervention to preserve limb. Validated medical therapy continues post-revascularization. Specialty coordination including vascular surgery, cardiology, and primary care is essential.
How long does it take for PAD therapy to show results?
PAD therapy results develop progressively. Statin LDL reduction develops within 4 to 6 weeks. Antiplatelet effects begin within days. Cilostazol walking distance improvements typically develop over 12 to 24 weeks. Supervised exercise therapy improvements develop over 12 weeks of structured programs. Smoking cessation cardiovascular benefits begin within months and continue improving over years. Semaglutide STRIDE walking distance improvements were documented at 52 weeks. Sustained intervention is required.
Should I take antiplatelets and Wegovy together for PAD with obesity?
Yes, when both are appropriate per individual indications. Validated antiplatelets are foundational for PAD secondary prevention per AHA/ACC 2016. Wegovy (semaglutide) holds FDA approval for chronic weight management and CV risk reduction in obesity without diabetes via SELECT 20 percent MACE reduction. Combination therapy is common in clinical practice. Bleeding risk monitoring is appropriate. Specialty coordination including primary care, vascular medicine, and cardiology ensures appropriate matching.
What questions should I ask my doctor about peptides for PAD?
Ask: (1) What is my comprehensive evaluation including ABI, lipid panel, ASCVD risk, smoking history, and CLTI assessment? (2) Am I on optimal antiplatelet therapy (aspirin, clopidogrel, or rivaroxaban plus aspirin per COMPASS)? (3) Am I on optimal statin therapy at appropriate intensity? (4) For symptomatic claudication, am I a candidate for cilostazol (Pletal) and supervised exercise therapy? (5) For PAD with T2DM, am I a candidate for semaglutide (Ozempic) given STRIDE evidence? (6) Is smoking cessation optimized? (7) Do I need vascular surgery evaluation?
Medical Disclaimer
This content is for educational and informational purposes only and does not constitute medical advice. The information presented reflects published research as indexed by PSI and should not be used to make treatment decisions. Always consult a qualified healthcare provider before starting, stopping, or modifying any treatment.